Latest Regentis Biomaterials News & Updates

See the latest news and media coverage for Regentis Biomaterials. We track all announcements, press releases, and industry mentions in real time, all in one place.

Regentis Biomaterials

Regenerative medicine company developing hydrogel implants for orthopedic tissue repair

regentis.co.il

Headquarters: Herzliya, Israel
Company type: Public company
Number of employees: 10–50
Industry: Biotechnology & Medical Research

Last updated Today

Latest news about Regentis Biomaterials

In short: Regentis Biomaterials advanced its GelrinC pivotal trial, secured new patents, and prepared for a 2026 European commercial rollout.

Company announcements

Yesterday Regentis Biomaterials

Regentis Biomaterials approves solvent-free GelrinC process

European regulatory approval boosts yield by 400%, enabling scaling for commercial demand.

August 14 Regentis Biomaterials

Regentis Biomaterials builds commercial case for GelrinC

The product targets the multi-billion dollar knee cartilage repair market, highlighting its commercial potential for investors.

August 13 Regentis Biomaterials

Regentis Biomaterials builds manufacturing and IP powerhouse

A Japan patent allowance protects its solvent-free, 5-fold higher-yield GelrinC manufacturing; EU commercialization begins 2026 and U.S. pivotal trial is over 50% enrolled.

May 18 Regentis Biomaterials

Regentis Biomaterials develops and patents new manufacturing process

The solvent-free process increases GelrinC production yield by 400%.

Media coverage

September 11 USA Today

Regentis Biomaterials Reports First Half 2026 Financial Results and Provides Corporate Update

Advances GelrinC® U.S. pivotal trial with 43 patients treated; Completion of enrollment expected by approximately year...

September 11 Becker's Spine Review

Regentis advances pivotal knee cartilage implant trial

Regentis Biomaterials has treated 43 of 80 patients in its pivotal U.S. trial evaluating GelrinC, a hydrogel implant for focal articular knee cartilage injuries. The...

August 27 Markets Insider

Regenerative Hydrogel Is Redefining Cartilage Repair as Regentis Advances GelrinC

Austin, Texas, August 28th, 2026, FinanceWireResearchers are developing new regenerative approaches, including stem cells, ...

August 17 Markets Insider

Regentis Biomaterials (NYSE American: RGNT) Moves GelrinC Along Parallel US Clinical and European Commercial Tracks

Austin, Texas, August 17th, 2026, FinanceWireRegentis has passed 50% enrollment in the pivotal Phase III SAGE study of...

Never miss news about Regentis Biomaterials

Track Regentis Biomaterials and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Regentis Biomaterials competitors & trending companies

Browse news for competitors to Regentis Biomaterials and other trending companies.